import{_ as Q,c as B,o as N,ag as l}from"./chunks/framework.Bw-5EFTY.js";const U="data:image/png;base64,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",t="data:image/png;base64,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",E=JSON.parse('{"title":"兒童發展、疫苗","description":"","frontmatter":{"title":"兒童發展、疫苗","updated":"2025-02-13T21:58:10.000Z","created":"2025-02-13T15:36:50.000Z"},"headers":[],"relativePath":"pediatrics/兒內/兒童發展、疫苗.md","filePath":"pediatrics/兒內/兒童發展、疫苗.md"}'),i={name:"pediatrics/兒內/兒童發展、疫苗.md"};function X(d,A,g,n,V,C){return N(),B("div",null,A[0]||(A[0]=[l('<p>兒童發展、疫苗 2025年2月13日 下午 03:36</p><ul><li><p>兒童疫苗概論:</p><ul><li>台灣疫苗接踵紀錄表:</li><li><img src="'+U+'" alt="image1"></li><li>疫苗接種： <ul><li>與外在病原體暴露有關，應依出生後年紀來計算(無論是否早產)</li></ul></li><li>生長發育： <ul><li>以矯正年齡作爲參考</li></ul></li><li>時程 <ul><li>出生後24 小時內： HBV 1</li><li>1 個月大： HBV2</li><li>2 個月大： DTaP-Hib-IPV 1 、PCV13 1</li><li>4 個月大： DTaP-Hib-IPV 2 、PCV13 2</li><li>5 個月大： BCG</li><li>6 個月大： DTaP-Hib-IPV 3 、HBV3、(流感開打)</li><li>12 個月大： PCV13 3 、MMR 、Varicella 、HAV 1</li><li>15 個月大： 日本腦炎(JE) 1</li><li>18 個月大： DTaP-Hib-IPV 4 、HAV2</li><li>27 個月大： 日本腦炎(JE) 2</li><li>2025/1：HAV改18.27施打(降低A肝疫苗第1、2劑常發生接種間隔不足之誤失)</li><li>DTaP-Hib-IPV：五合一</li><li>白喉、破傷風、百日咳、B型嗜血桿菌、不活化小兒痲痺: <ul><li>2.4.6.18個月</li><li>孕婦：百日咳疫苗建議於28週至36週施打，可以提升胎兒出生後對於百日咳的免疫力</li></ul></li></ul></li></ul></li><li><p>疫苗個論</p><ul><li>活性減毒疫苗 <ul><li>不可施打的情況： <ul><li>Immunocompromised</li><li>懷孕</li><li>3 個月內肌肉注射HBV IG</li><li>6 個月內輸過血或接受靜脈血品(washed RBC 除外)</li><li>11 個月內IVIG &gt; 2 g/kg(高劑量)</li><li>1 個月內使用超過2 mg/kg/day prednisone</li><li>在1個月內， 10 kg 以上的孩童用20 mg/day prednisone 以上，且使用超過2 星期</li></ul></li></ul></li></ul></li><li><p>[口訣： JR MV BOY]</p><ul><li>J= 日本腦炎</li><li>R＝輪狀病毒</li><li>M=MMR</li><li>V＝水痘(varicella)</li><li>B=BCG</li><li>O=口服沙賓</li><li>Y＝黃熱病</li></ul></li><li><p>水痘疫苗：</p><ul><li>1劑水痘疫苗：保護力大約86%，減少、預防水痘感染造成的重症</li><li>成人水痘新舊疫苗比較</li><li></li></ul></li></ul><table tabindex="0"><thead><tr><th><strong>項目</strong></th><th><strong>Shingrix (GSK)</strong></th><th><strong>Zostavax (MSD)</strong></th></tr></thead><tbody><tr><td><strong>適用年齡</strong></td><td>50 歲以上</td><td>50 歲以上</td></tr><tr><td><strong>劑數</strong></td><td>2 劑</td><td>1 劑</td></tr><tr><td><strong>接種間隔</strong></td><td>兩劑相隔 2-6 個月</td><td>無</td></tr><tr><td><strong>接種方式</strong></td><td>肌肉注射 (IM)</td><td>皮下注射 (SC)</td></tr><tr><td><strong>疫苗類型</strong></td><td>重組疫苗</td><td>減活疫苗</td></tr><tr><td><strong>疫苗成分</strong></td><td>非活性抗原 (gE)</td><td>Oka/Merck 水痘帶狀皰疹病毒</td></tr><tr><td><strong>免疫功能低下者可否接種</strong></td><td>可</td><td>不適合</td></tr><tr><td><strong>禁忌</strong></td><td>對疫苗成分過敏者</td><td>對疫苗成分過敏者、免疫缺乏者、使用免疫抑制藥物者</td></tr><tr><td><strong>整體保護效能</strong></td><td>較高</td><td>較低</td></tr><tr><td><strong>後遺神經痛 (PHN) 保護效能</strong></td><td>較高</td><td>較低</td></tr><tr><td><strong>預防帶狀皰疹併發症保護效能</strong></td><td>較高</td><td>無相關數據</td></tr><tr><td><strong>CDC 建議</strong></td><td>50 歲以上皆建議接種，特別是免疫功能低下者</td><td>建議曾接種者再接種 Shingrix，不建議 50-59 歲接種</td></tr><tr><td><strong>市場狀況</strong></td><td>現行建議使用</td><td>美國已於 2020 年退市</td></tr></tbody></table><ul><li><p>流感疫苗</p><ul><li>出生滿6個月即可施打，每年冬季打一次</li><li>8歲以下初次接種需打第二劑(兩劑間隔4週)</li><li>禁忌症：高燒、急性疾病、先前接種該項疫苗曾發生嚴重反應或未經治療的結核病患</li></ul></li><li><p>輪狀病毒疫苗：</p><ul><li>年紀較大的孩童上可能導致腸套疊，不建議大於8 個月大之兒童接種疫苗</li><li>RotaTeq 羅逹停：打滿才有保護力，效果較久 <ul><li>口服3 劑，出生後滿2 、4 、6 個月各口服一劑； 8 月大前接種完成</li></ul></li><li>Rotarix 羅特律：保護力較快出現，但維持時間較短 <ul><li>口服2 劑，出生後滿2 、4 個月分別服用一劑； 6 月大前接種完成</li></ul></li></ul></li><li><p>RSV單株抗體(Palivizumab、Nirsevimab)：</p><ul><li>直接施打抗體，必須持續施打才能獲得保護力</li><li>健保給付族群： <ul><li>出生時懷孕週期&lt;33週的早產兒</li><li>併有呼吸道結構、功能異常之慢性肺疾病早產兒（35週以下）</li><li>具重大血流動力學異常的先天性心臟病童</li><li>所有年齡&lt;8個月在RSV流行季節期間(僅能使用Nirsevimab)</li></ul></li><li>肺炎鏈球菌疫苗: <ul><li>肺炎鏈球菌表面莢膜多醣(capsularpolysaccharide)與致病力有關，至少有90種血清型</li><li>潛伏在鼻腔內，當免疫力降低可侵入呼吸道或血液中而引發肺炎、菌血症、腦膜炎等嚴重病症，稱為侵襲性肺炎鏈球菌疾病感染症(IPD)，也是幼兒中耳炎、鼻竇炎最常見 的病原。</li><li>高罹病率族群： <ul><li>5歲以下幼童及65歲以上老人為2大高罹病率族群</li><li>不論年齡高危險群： <ul><li>①脾臟缺損</li><li>②先天或後天免疫功能不全(愛滋病毒感染)</li><li>③人工耳植入者</li><li>④慢性疾病：慢性腎病變、慢性心臟疾病、慢性肺臟病、糖尿病、慢性肝病與肝硬化患者、酒癮者、菸癮者</li><li>⑤腦脊髓液滲漏者</li><li>⑥接受免疫抑制劑或放射治療的惡性腫瘤者或器官移植者</li></ul></li></ul></li><li>出生2個月即可打13價第一劑</li><li>23價為多醣體抗原，2歲以下嬰幼兒對其免疫反應不佳</li></ul></li></ul></li><li><p>破傷風:</p><ul><li>五合一預防接種保護力至20歲</li><li>低風險：10年內是否施打</li><li>高風險：5年內是否施打</li></ul></li><li><p>狂犬病:</p><ul><li>疫苗注射 <ul><li>暴露前： 注射3劑疫苗，分別爲第0 、7 、21或28天(衛服部2018) <ul><li>WHO 2022：2劑，0、7天</li><li>高風險族群必需在可能的暴露發生前1個月以上事先安排與規劃</li></ul></li><li>暴露後： 第0、3、7、14天各接種1劑</li><li>病人有接受過暴露前預防接種：只需再施打2劑(第0、3天)</li></ul></li><li>暴露後免疫球蛋白HRIG (human rabies immunoglobulin) 的使用原則： <ul><li>施打：與疫苗同時，或首劑疫苗施打後7天內施打</li><li>不施打：首劑疫苗施打超過7天(已產生免疫力不需要被動免疫)、已接受暴露前預防接種、曾接受完整暴露後預防接種</li><li>下圖節錄自<a href="https://bit.ly/2GWJQEx" target="_blank" rel="noreferrer">狂犬病防治工作手冊</a></li></ul></li></ul></li></ul><p><img src="'+t+'" alt="image2"></p><ul><li>小補充： <ul><li>疫苗接種觀念： <ul><li><strong>活性 + 活性:</strong><ul><li><strong>可同時</strong></li><li><strong>不同時間施打時，除了</strong>BCG 和口服活性疫苗，其他都須間隔至少28天</li></ul></li><li><strong>活性 + 非活性:</strong><ul><li><strong>霍亂與黃熱病不可同時施打，其餘皆可。</strong></li><li><strong>不同時間施打時霍亂與黃熱病需間隔 3 週，其餘沒限制。</strong></li></ul></li><li><strong>非活性 + 非活性</strong>: <ul><li>沒有限制</li></ul></li></ul></li><li>口服疫苗(台灣)：輪狀病毒、小兒痲痺(口服沙賓)</li></ul></li></ul>',6)]))}const I=Q(i,[["render",X]]);export{E as __pageData,I as default};
